Nectar Lifesciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	9.63×	3.33×	0.70×	0.27×	0.57×
	0.28×	1.44×	1.82×	0.20×	8.20×
	−1,789.1%	—	−5.3%	5.5%	−0.3%
	0.00×	0.00×	0.79×	0.77×	0.67×
	1.07×	1.07×	2.14×	2.05×	2.06×
	0.0%	—	−11.5%	0.5%	−2.2%
	−38.1%	−38.1%	−11.2%	0.5%	−2.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NECLIFE₹10.33

Nectar Lifesciences Limited

· Pharma & Health

₹ CrorePeersAAREYDRUGS NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹201 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.57	0.27	0.70	3.33	9.63
Interest Burden (Pretax/EBIT) ×	8.20	0.20	1.82	1.44	0.28
EBIT Margin %	-0.34	5.48	-5.31	—	-1,789.06
Asset Turnover ×	0.67	0.77	0.79	0.00	0.00
Financial Leverage (Assets/Equity) ×	2.06	2.05	2.14	1.07	1.07
ROE (5-step product, year-end total equity) %	-2.19	0.47	-11.49	—	-0.00
ROE (owners' profit / average owners' equity) %	-2.25	0.47	-11.23	-38.08	-38.08

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.